Introduction and hypothesis Intra-vaginal diazepam suppositories are commonly prescribed as a treatment option for high-tone pelvic floor myalgia. This triple-blinded placebocontrolled randomized trial sought to determine if 10 mg diazepam suppositories improve resting pelvic floor electromyography (EMG) compared with placebo. Methods Women ≥18 years of age with hypertonic pelvic floor muscles on examination, confirmed by resting EMG ≥2.0 microvolts (μv), administered vaginal suppositories containing either diazepam or placebo for 28 consecutive nights.
Introduction
Pelvic floor disorders encompass a variety of conditions including pelvic organ prolapse, urinary incontinence and urgency, vulvar disease, dyspareunia, and fecal incontinence. Within this broad scope, a subset of patients exists who suffer from a condition known as high-tone pelvic floor dysfunction (HTPFD), or levator myalgia. These women present with pelvic pain characterized by an increase in pain with internal vaginal examination or penetration, which may lead to unprovoked vaginal pain due to levator hypercontractility.
While the prevalence of HTPFD is unknown, it is largely believed to be under diagnosed [1] . Contributing factors include an elusive presentation, anxiety or embarrassment causing hesitation in seeking care, and lack of provider awareness of the condition. An experienced examiner and an appropriate index of suspicion are required to identify the condition. Current treatment regimens include pelvic floor physical therapy [2, 3] , biofeedback [4] , behavioral modification, medications such as antidepressants, acupuncture [5] , and trigger point injections [6] . Recently, treatments, such as intra-vaginal diazepam used off-label, have shown a suggested benefit in HTPFD. Nevertheless, the literature surrounding diazepam use is limited [1] .
Therefore, the purpose of this study was to evaluate the use of intra-vaginal diazepam suppositories compared with placebo for the treatment for HTPFD. We hypothesized that diazepam suppositories used nightly for 28 consecutive nights would decrease resting pelvic floor tone when evaluated by electromyography (EMG). Secondary outcomes included sexual function, pain, and health-related quality of life measured using validated questionnaires.
Materials and methods
This was a triple-blinded randomized placebo-controlled trial. The principal investigator, study subjects, data collectors, and the statistician were all blinded to the randomization allocation until completion of all statistical analysis. Local institutional review board approval was obtained, and the study was registered through the US National Institutes of Health Clinical Trials Registry, NCT01233791. All participants gave written informed consent and were limited to the patients of the Division of Urogynecology and Reconstructive Pelvic Surgery at Good Samaritan Hospital, Cincinnati, Ohio, USA. No subjects were elicited through advertisement.
Subjects were eligible for enrollment if they were English-speaking, at least 18 years of age, and if they had been diagnosed with high-tone pelvic floor dysfunction by the treating urogynecologist (Fig. 1) . All patients presenting with high-tone pelvic floor during the study period were approached for enrollment. Those with concurrent diagnosis of comorbid conditions, such as endometriosis or painful bladder syndrome, were included. Subjects were excluded if they had an allergy to diazepam or any benzodiazepine, were currently receiving pelvic floor physical therapy, had undergone pelvic surgery within the 3 months prior to enrollment, were currently pregnant, or had any contraindication to diazepam. The use of any benzodiazepines, narcotics, or alcohol on a regular basis (defined as daily use) was also a reason for exclusion. Contraindications include hepatic or renal dysfunction, myasthenia gravis, acute narrow angle glaucoma, severe respiratory insufficiency, or sleep apnea. A history of receiving pelvic floor physical therapy did not preclude inclusion unless treatment occurred in the 6 months prior to enrollment.
Potential candidates were approached by the research nurse or principal investigator and informed of the study. Following consent to participate, all subjects underwent vaginal surface EMG. Vaginal EMG measurements were taken at states of rest and during several exercises of the pelvic floor. These were obtained by one of two trained personnel, the research nurse or principal investigator, in order to reduce error. A T-shaped, vaginal EMG sensor (Thought Technology Ltd., Quebec, Canada; Fig. 2 ) was used for all EMG measurements. The design and shape of the probe allowed for consistent placement, with the cross bar of the t-shape resting on the perineum when placed appropriately. Following each group of pelvic floor exercises or periods of rest, the sensor was evaluated to ensure it had not moved. If movement had occurred, it was repositioned and the exercises repeated. The assessments included a short (30-s) tonic contraction, 5 rapid contractions, 3 long (60-s) interval contractions, and a long (60-s) tonic contraction. The primary outcome, resting pelvic floor tone, consisted of a series of 4 measurements taken at different points of rest throughout the pelvic floor exercises mentioned above. These included: pre-protocol rest, rest following 5 rapid contractions, rest following 3 long interval contractions, and a final rest period after the 60-s tonic contraction. All EMG measurements were collected using a computer-based system (MyoTrac3, Version 1.2, 1997). As the primary objective was improvement in high-tone pelvic floor dysfunction, only subjects with a pre-protocol resting EMG measurement ≥2.0 μv were considered eligible for study completion. Study randomization, to treatment or placebo, was revealed by opening a sequentially numbered, opaque, sealed envelope.
In addition to electromyography measures, two additional measures were collected. A modified Oxford scale was obtained at baseline and repeated at 4 weeks by the same examiner. The functional status of the pelvic floor muscles was also categorized as: normal muscles that can voluntarily and involuntarily contract and relax, overactive muscles that do not relax, or may even contract when relaxation is functionally needed, underactive muscles, which cannot voluntarily contract when appropriate, and non-functioning muscles, where there is no palpable muscle action.
Several validated questionnaires were completed at baseline. These included the Female Sexual Function Index (FSFI), a quadruple Visual Analog Scale (VAS), the Short Form Health Survey 12 (SF-12), and the Patient Global Impression of Severity (PGI-S). These four questionnaires, follow-up vaginal EMG measurements, and the Patient Global Impression of Improvement (PGI-I) were collected at 2 and 4 weeks following commencement of suppository usage.
The FSFI is a 19-item, validated questionnaire used to screen subjects for sexual disorders. Six domains are assessed with a maximum overall score of 36. The domains of desire, arousal, orgasm, satisfaction, lubrication, and pain are also scored individually. Subjects with overall scores ≤26.55 are considered at risk of sexual dysfunction [7] .
The SF-12 Health Survey is a brief version of the SF-36. This general health questionnaire is designed to evaluate a subject's health-related quality of life in a physical and mental component. Subjects scoring above 50 are considered to have average or better health. Scores less than 50 represent less than average quality of life as a result of the subject's medical health [8] .
Four visual analog scales (VAS) were utilized to assess pelvic pain levels. These were administered in the standard 100-mm format with instructions to place an "x" on the line indicating the subject's response to each of the questions. VAS questions queried regarding pain level right now, average or typical pain level, pain level at its best, and pain level at its worst [9] .
Subjects also completed two additional items: the Patient Global Impression of Severity (PGI-S) and the Patient Global Impression of Improvement (PGI-I). Each of these questionnaires consists of a single question scored using a Likert scale. The PGI-S assesses perceived severity of pain "right now" from normal to severe. The PGI-I assesses perceived improvement from very much better to very much worse [10, 11] . Both written and verbal instructions for appropriate use and application of the vaginal suppository were provided. Written instructions were given in the form of a Patient Administration Leaflet (PAL; Fig. 3 ). The pharmacist, in coordination with the principal investigator, constructed a PAL specifically for intra-vaginal administration of the suppositories. The PAL included a diagram illustrating the posterior fornix as the optimal location for suppository placement. When given verbal instructions, subjects were asked to place the suppository as high in the vagina as possible. Subjects were given the option to place the suppository digitally or with an applicator. Instructions were given to use one suppository every night for 28 consecutive nights before going to sleep. This time of administration was chosen to avoid any theoretical sedative effects from the diazepam. Subjects were given routine precautions for benzodiazepine use including: avoiding operating heavy machinery, no driving after taking the medication, and the potential for drowsiness. Average menstrual cycle length and decreased compliance with longer treatment regimens guided the design for 28 days of treatment.
A written prescription for "suppository A" or "suppository 1" was provided for each participant. All investigators, research nurses, and subjects were blinded to the study arm. The compounding pharmacist was the only individual with knowledge of randomization allocation; pharmacy staff were unaware of the randomization key. The pharmacy was located off-site. A map and directions were given if the patient preferred to obtain the suppository from the pharmacy, or the suppository could be shipped directly to their home. The suppositories were white in color, weighed about 2 g each, and contained 10 mg of diazepam. Diazepam is a benzodiazepine known for treatment of muscle spasms, status epilepticus, acute alcohol withdrawal, and anxiety. The onset of action is variable depending on the route of administration. The half life of the medication has a wide range, 20 to 100 h, with longer elimination required for those with renal or hepatic dysfunction. Notwithstanding, the onset of action and half life of vaginally administered diazepam has not been determined. Diazepam powder was supplied to the pharmacist by the Professional Compounding Centers of America (Houston, TX, USA). Both diazepam and placebo formulations used an identical polyethylene glycol base commonly used for rectal and vaginal suppositories. There was no visual difference between the active and placebo suppositories, and absorption of the base was designed to be similar.
In order to compensate the subjects for their time and travel, a stipend of $100 was provided following the final study visit. Funding was provided through an educational grant from the TriHealth Good Samaritan Hospital's Medical Education Research Fund.
An a priori sample size calculation indicated that 14 patients would be needed to detect a difference of 2 μv in resting EMG measurement with a power of 90 % and a significance level of 0.05 (nQuery Advisor, version 7.0, Statistical Solutions, Saugas, MA, USA). This difference was selected as a clinically relevant change based on physical therapy literature [12] [13] [14] . Additionally, to confirm the clinical significance of such a change, expert opinion was sought from three pelvic floor physical therapists. The randomization schedule was created using nQuery Advisor with a 1:1 ratio using mixed blocks. Descriptive statistics were calculated for demographics and dependent variables. A repeated measures ANOVA was 
Results
Twenty-one patients were approached to participate between September 2010 and December 2011; all agreed to enroll in the study. Eleven were randomized to placebo and 10 to diazepam (CONSORT Flow Diagram, Fig. 1 ). One patient in the placebo group did not return for the first study visit. One patient in each group was lost to follow-up, and 2 subjects in each group were excluded owing to a baseline pre-protocol EMG measurement of less than 2 μv. Thus, 14 subjects completed the study; 7 received diazepam and 7 placebo. The majority were Caucasian (85.7 %), with a mean age of 36.1 (SD 13.9), and a mean body mass index (BMI) of 28.56 (SD 9.4; Table 1 ). Concurrent diagnosis of endometriosis or painful bladder syndrome was noted in 4 subjects. The pelvic organ prolapse quantification examination (POPQ) revealed little to no prolapse in the group, although 5 subjects had previously undergone hysterectomy with oophorectomy. A large proportion (57 %) had a history of depression or anxiety, with the majority taking medication for their condition. Only 3 patients were not sexually active within the 4 weeks prior to enrollment. History of prior physical therapy was not common; one subject had undergone pelvic floor physical therapy for their discomfort.
Average baseline EMG measurements for pre-protocol rest was 3.16 μv (SD 0.88) for the diazepam arm and 2.7 μv (SD 0.34) for the placebo arm. There was no difference between groups at baseline for any of the four resting measures (Table 2) . Using the quadruple VAS, patients reported their pelvic pain at the time of the office visit to be 4.0, average pain to be 5.5, best pain level 2.0, and worst pain level 8.7 (Table 2) . Again, no difference between groups was found at baseline. When evaluating the SF-12, we found that both the physical and mental component scores indicated a lower than average quality of life as a result of their health status. Mean scores for the physical and mental components of the SF-12 for all subjects were 40.4 (SD 14.9) and 39.3 (11.5; Table 2 ). The FSFI was utilized to investigate baseline sexual function. Not surprisingly, the total FSFI score for the group was quite low, with a median total score of 13.4 (IQR 9.6, 17.2; Table 2 ).
Outcome measures were analyzed using repeated measures ANOVA or analogous non-parametric procedures where appropriate. For all resting vaginal EMG measurements, diazepam did not significantly improve resting tone. No interaction effect was noted, nor was there a difference within groups (Table 3) . However, between-groups ANOVA revealed a significant difference in 2 of the 4 measures: rest period following rapid contractions and post-protocol rest. The betweengroups ANOVA eliminates the variable of time and averages all three data collection points into one measurement. Surprisingly, this difference favored the placebo group.
Scores on the validated questionnaires were then assessed for the different time points. When evaluating the PGI-I, there was no interaction and no significant difference within subjects or between groups (Table 3) . However, when evaluating the PGI-S there was a significant improvement within subjects (p=0.002), giving evidence to suggest that care and attention by a provider may play a therapeutic role.
For the SF-12, both the active and placebo groups improved over time in the mental and physical scores. This change, however, was not significant, and there was no difference between groups nor was an interaction effect noted (Table 3) . Modest improvements were noted in the VAS for pain. Scores for "pain level right now" and "pain level at its worst" improved for both groups, although this was not found to be significant. The repeated measures evaluation of the FSFI showed no difference within subjects or between groups at any of the three measurement times (Table 3) .
Finally, to evaluate alternative classifications of muscle function, the modified Oxford and the functional categories at baseline and 4 weeks were analyzed. No significant alterations were noted in measures over this time frame. While previous research in this area is limited, our study contradicts those that exist to date. Rogalski et al. reported improvements in muscle tone using perineometry during three phases: resting, squeezing, and relaxation following squeeze with the use of vaginal diazepam [1] . The study was retrospective, had no control arm, and subjects were undergoing concurrent pelvic floor physical therapy and intramuscular trigger point injections. The confounding effects of parallel treatments as well as the retrospective design may have led to potential bias that could explain the disparate findings. Nevertheless, Rogalski's paper did provide reassurance as to the low risks of side effects related to intravaginal diazepam use.
Most of the literature surrounding HTPFD documents pelvic floor physical therapy and trigger point injections as the mainstays of therapy [15] . The current reported success of trans-rectal massage of the pelvic floor approximates 61 % [16] . While trigger point injections are often less effective, up to 33 % of subjects may be pain free after this modality [17] . Our results show that intra-vaginal diazepam is a poor substitute for these types of treatment.
Regardless of treatment arm, we did document an improvement in the patients' impression of pain severity, improvement in the subjects' overall health-related quality of life from physical and mental aspects, and improvement in pain levels for average pain and worst pain. Possible explanations include a potential for treatment effect in both groups and the influence of provider care and attention. Often, the impact of talking with patients and validating their pain is therapeutic in itself. Future research on this influence on subjects with chronic pain would be of use. Additionally, studies into the pharmacokinetics of vaginally administered diazepam would establish the appropriate dosage and frequency required to achieve musculoskeletal impact.
There are several strengths to the study. Subjects were required to have high-tone pelvic floor muscles not only by physician examination, but also by objective measurement with surface EMG. This confirms the diagnosis, as well as the role of treatment, and renders the study findings reproducible. Outcome measures were both objective and subjective, with use of EMG measurements and questionnaire data. Although surface EMG is a measure of electrical activity given off by the muscle and not a direct measure of vaginal muscle tone, it is often used as a surrogate [18] . Several validated questionnaires were utilized to assess a variety of symptoms including pain and sexual function. Lastly, this study was triple blinded. The subjects, investigators, data collectors, and statisticians were all blinded to the randomization allocation.
There are limitations to our study. Although we performed an a priori power calculation, it is possible that our sample size was not large enough to detect a true difference. We are not able to verify with certainty that each subject used the suppository as requested, every night for 28 days. It is also feasible that a higher dosage, more frequent dosing, or longer treatment cycle is necessary to appreciate any true improvement in objective or subjective outcomes with diazepam. The group consisted of refractory cases as well as new or early diagnosis. This could have impact on the time to response of treatment or the dose and frequency required for improvement. Evaluation of the raw data revealed a large standard deviation for all resting EMG measurements, possibly contributing to these unexpected findings. As is common in this patient population, several patients carried concurrent diagnoses thought to be associated with or contribute to high-tone pelvic floor such as endometriosis or painful bladder syndrome. Nevertheless, we did not evaluate use of vaginal diazepam in conjunction with other traditional treatments for HTPFD such as physical therapy and trigger point injections, as was performed in the prior retrospective study [1] . It is possible that such treatments together provide a synergistic benefit that was not measurable in this cohort. Furthermore, it was not feasible in this design to perform EMG measures at a standardized time of day for all subjects, which could have impacted the results. Future study would benefit from such modifications, or the use of a crossover design with a washout period to reduce confounders.
In this study, 10-mg vaginal diazepam suppositories used for 28 nights did not improve high-tone pelvic floor dysfunction compared with placebo. Therefore, such a dose or duration of vaginal diazepam alone is a poor substitute for pelvic floor physical therapy or intra-vaginal trigger point injections.
Further work in this area may help shed more light on the role of diazepam in the treatment of this debilitating condition.
